STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Files An 8-K Regulation FD Disclosure

STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

On August 30, 2018 Strata Skin Sciences, Inc. (the "Company") and a member of the Company's board of directors, Uri Geiger, in his individual capacity (and together with the Company, the"plaintiffs"), filed a complaint seeking an Action for a Declaratory Judgment in the Court of Common Pleas, Montgomery County, Pennsylvania, against Ra Medical Systems, Inc., a Delaware Corporation with a principal place of business at 2070 Las Palmas Drive, Carlsbad, CA 92011.
Story continues below

In the action, the plaintiffs are seeking a declaration that the plaintiffs are not liable to the defendant, Ra Medical Systems, for any reason, including but not limited to claims of tortious interference, defamation, libel, or unfair competition and did not tortuously interfere with defendant, Ra Medical Systems', initial public offering or engage in any other wrongdoing as a result of statements made by Mr. Geiger, about which defendant, Ra Medical Systems, has threatened to sue the Company. The declaratory judgment action also seeks a declaration that neither plaintiff has made an actionable statement to UBS Investment Bank regarding defendant, Ra Medical Systems', potential initial public offering.

A copy of the Action for Declaratory Judgment is submitted herewith as Exhibit 99.1`

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits

Exhibits.

Exhibit Number

Description

99.1

Action For Declaratory Judgment

Exhibit Index

Description

99.1

Action For Declaratory Judgment


STRATA Skin Sciences, Inc. Exhibit
EX-99.1 2 ex_99-1.htm ACTION FOR DECLARATORY JUDGMENT – NOTICE TO PLEAD EXHIBIT 99.1           STRATA SKIN SCIENCES,…
To view the full exhibit click here

About STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN)

STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.

An ad to help with our costs